185 related articles for article (PubMed ID: 21479369)
21. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
[TBL] [Abstract][Full Text] [Related]
22. A case-control study on the SNP309T → G and 40-bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer.
Jalilvand A; Yari K; Aznab M; Rahimi Z; Salahshouri Far I; Mohammadi P
J Clin Lab Anal; 2020 Dec; 34(12):e23529. PubMed ID: 32951271
[TBL] [Abstract][Full Text] [Related]
23. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS
Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836
[TBL] [Abstract][Full Text] [Related]
24. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
Zhao E; Cui D; Yuan L; Lu W
Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
[TBL] [Abstract][Full Text] [Related]
25. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
[TBL] [Abstract][Full Text] [Related]
26. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.
Qin X; Peng Q; Tang W; Lao X; Chen Z; Lai H; Deng Y; Mo C; Sui J; Wu J; Zhai L; Yang S; Li S; Zhao J
PLoS One; 2013; 8(9):e76031. PubMed ID: 24098760
[TBL] [Abstract][Full Text] [Related]
27. TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: evidence from an updated meta-analysis.
Peng Q; Lao X; Chen Z; Lai H; Deng Y; Wang J; Mo C; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
PLoS One; 2013; 8(12):e82773. PubMed ID: 24376578
[TBL] [Abstract][Full Text] [Related]
28. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
29. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.
Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
Hum Cell; 2009 Nov; 22(4):101-6. PubMed ID: 19874399
[TBL] [Abstract][Full Text] [Related]
31. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
32. Contribution of Murine Double Minute 2 Genotypes to Colorectal Cancer Risk in Taiwan.
Yueh TC; Hung YW; Shih TC; Wu CN; Wang SC; Lai YL; Hsu SW; Wu MH; Fu CK; Wang YC; Ke TW; Chang WS; Tsai CW; Bau DT
Cancer Genomics Proteomics; 2018; 15(5):405-411. PubMed ID: 30194081
[TBL] [Abstract][Full Text] [Related]
33. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
34. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
Fang S; Krahe R; Lozano G; Han Y; Chen W; Post SM; Zhang B; Wilson CD; Bachinski LL; Strong LC; Amos CI
PLoS One; 2010 May; 5(5):e10813. PubMed ID: 20520810
[TBL] [Abstract][Full Text] [Related]
35. [Genetic polymorphism in MDM2 is associated with susceptibility to colorectal cancer in a Chinese population].
Liu JN; Zhang XM; Guo YL; Sun T; Lin DX; Wen T
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):335-8. PubMed ID: 18953830
[TBL] [Abstract][Full Text] [Related]
36. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
[TBL] [Abstract][Full Text] [Related]
37. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
38. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma.
Singhal P; Hussain S; Thakur N; Batra S; Salhan S; Bhambani S; Bharadwaj M
DNA Cell Biol; 2013 Jan; 32(1):19-27. PubMed ID: 23210739
[TBL] [Abstract][Full Text] [Related]
39. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
40. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.
Ma H; Hu Z; Zhai X; Wang S; Wang X; Qin J; Jin G; Liu J; Wang X; Wei Q; Shen H
Cancer Lett; 2006 Aug; 240(2):261-7. PubMed ID: 16288830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
